Abbott received FDA approval for its Amplatzer Paraclose PVL Occluder, the first transcatheter device designed to close paravalvular leaks around surgical replacement heart valves without requiring additional open-heart surgery.
Families who lost loved ones are demanding a ban on an 'intrusive' camera monitoring system used in approximately half of England's mental health wards, citing misuse and concerns about patient safety. The Oxevision system has been linked to avoidable deaths and required patients to wait up to 72 hours for approval to turn cameras off.
Outro, a New York-based neuroscience platform that helps patients safely discontinue psychiatric medications, announced it raised $7 million in combined pre-seed and seed funding. The funding will support the company's mission to close America's deprescribing gap and advance research in partnership with academic institutions.
An investigation by CalMatters and The Markup reveals that patients attempting to opt out of health data sharing through Epic Systems' MyChart platform encounter a complex and frustrating process, raising privacy concerns about how medical records are used.
The FDA has granted 510(k) clearance to Motivista, a prescription digital therapeutic developed by Click Therapeutics for adults with negative symptoms of schizophrenia. The treatment is cleared as an adjunct to clinician-managed outpatient care, addressing symptoms that current medications targeting hallucinations and delusions do not effectively treat.
Array Behavioral Care, a Chicago-based virtual behavioral health provider, introduced a new triage and routing capability designed to help healthcare providers better respond to patients requiring urgent mental health care.
Two new AI developments improve breast cancer risk prediction and detection: a deep learning model using 3D mammography (digital breast tomosynthesis) shows superior 5-year risk prediction compared to traditional 2D mammography-based AI, while AIIMS Delhi has developed an AI tool to serve as a second reader of mammograms, now licensed to BPL Technologies.
DeepHealth, a RadNet subsidiary, received FDA 510(k) clearance for an AI platform that automates breast ultrasound lesion detection, characterization according to ACR BI-RADS standards, and report generation. The technology aims to address the time-intensive, operator-dependent nature of ultrasound breast cancer screening.
The U.S. Food and Drug Administration has granted marketing authorization for Johnson & Johnson's OTTAVA robotic surgical system, enabling the healthcare conglomerate to enter the soft-tissue robotic surgery market for the first time.